ONCOPEPTIDES AB revenue breakdown overview

ONCOPEPTIDES AB revenue for the last year amounted to 31.70 M SEK, the most of which — 31.65 M SEK — came from its highest performing source at the moment, Targeted Therapies for Difficult-to-Treat Cancers, the year earlier bringing 35.22 M SEK. The greatest contribution to the revenue figure was made by Germany — last year it brought ONCOPEPTIDES AB 17.21 M SEK.